Towards a molecular classification of gliomas;Vers une classification moléculaire des gliomes

Bulletin du Cancer

Volumn 92, Issue 4, 2005, Pages 310-316

  Hoang Xuan, Khê ^a   Idbaih, Ahmed ^a   Mokhtari, Karima ^a   Sanson, Marc ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Astrocytoma; Glioblastoma; Glioma; Oligodendroglial tumor

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN P53;

ARTICLE; ASTROCYTOMA; CANCER CLASSIFICATION; CHEMOSENSITIVITY; CHROMOSOME 19Q; CHROMOSOME 1P; CHROMOSOME LOSS; GENE AMPLIFICATION; GENETIC ANALYSIS; GLIOMA; HISTOPATHOLOGY; HUMAN; MOLECULAR GENETICS; OLIGODENDROGLIA; OLIGODENDROGLIOMA; PREDICTION AND FORECASTING; PROGNOSIS; BRAIN TUMOR; CHROMOSOME 1; CHROMOSOME ABERRATION; CHROMOSOME DELETION; CLASSIFICATION; GENETICS; PATHOLOGY; PROTO ONCOGENE; REVIEW; TUMOR SUPPRESSOR GENE;

ASTROCYTOMA; BRAIN NEOPLASMS; CHROMOSOME ABERRATIONS; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 1; GENES, ERBB-1; GENES, P53; GLIOMA; HUMANS; OLIGODENDROGLIOMA; PROGNOSIS;

EID: 18344366398     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (84)

1. Behin A, Hoang-Xuan K, Carpentier AF, Delattre JY. Primary brain tumours in adults. Lancet 2003; 361: 323-31.
2. Cairncross JG, Macdonald DR. Successful chemotherapy for recurrent malignant oligodendroglioma. Ann Neurol 1988; 23: 360-4.
3. Burger PC. What is an oligodendroglioma? Brain Pathol 2002; 12: 257-9.
4. Coons SW, Johnson PC, Scheithauer BW, Yates AJ, Pearl DK. Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas. Cancer 1997; 79: 1381-93.
5. Daumas-Duport C, Varlet P, Tucker ML, Beuvon F, Cervera P, Chodkiewicz JP. Oligodendrogliomas. Part I: Patterns of growth, histological diagnosis, clinical and imaging correlations: a study of 153 cases. J Neurooncol 1997; 34: 37-59.
6. Giannini C, Scheirauer BW, Weaver AL, et al. Oligodendrogliomas: reproductibility and prognostic value of histologic diagnosis and grading. J Neuropathol Exp Neurol 2001; 60: 248-62.
7. Kleihues P, Cavenee WK. In: Pathology and genetics of tumours of the central nervous system. 2nd ed. Lyon (France): IARC Press (International Agency for Research on Cancer), 2000.
8. Mittler M, Walters BC, Stopa EG. Observer reliability in histological grading of astrocytoma stereotactic biopsies. J Neurosurg 1996; 85: 1091-4.
9. Watanabe K, Tachibana O, Sata K, Yonekawa Y, Kleihues P, Ohgaki H. Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. Brain Pathol 1996; 6: 217-23.
10. Reifenberger J, Ring GU, Gies U, Cobbers L, Oberstrass J, An HX, et al. Analysis of p53 mutation and epidermal growth factor receptor amplification in recurrent gliomas with malignant progression. J Neuropathol Exp Neurol 1996; 55: 822-31.
11. Bouvier-Labit C, Chinot O, Ochi C, Gambarelli D, Dufour H, Figarella-Branger D. Prognostic significance of Ki67, p53 and epidermal growth factor receptor immunostaining in human glioblastomas. Neuropathol Appl Neurobiol 1998; 24: 381-8.
12. Schmidt MC, Antweiler S, Urban N, Mueller W, Kuklik A, Meyer-Puttlitz B, et al. Impact of genotype and morphology on the prognosis of glioblastoma. J Neuropathol Exp Neurol 2002; 61: 321-8.
13. Ueki K, Ono Y, Henson JW, Efird JT, Von Deimling A, Louis DN. CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated. Cancer Res 1996; 56: 150-3.
14. Zhou XP, Li YJ, Hoang-Xuan K, Laurent-Puig P, Mokhtari K, Longy M, et al. Mutational analysis of the PTEN gene in gliomas: molecular and pathological correlations. Int J Cancer 1999; 84: 150-4.
15. Nakamura M, Watanabe T, Klangby U, Asker C, Wiman K, Yonekawa Y, et al. p14ARF deletion and methylation in genetic pathways to glioblastomas. Brain Pathol 2001; 11: 159-68.
16. Fleming TP, Saxena A, Clark WC, Robertson JT, Oldfield EH, Aaronson SA, et al. Amplification and/or overexpression of platelet-derived growth factor receptors and epidermal growth factor receptor in human glial tumors. Cancer Res 1992; 52: 4550-3.
17. Reifenberger G, Liu L, Ichimura K, Schmidt EE, Collins VP. Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations. Cancer Res 1993; 53: 2736-9.
18. Newcomb EW, Cohen H, Lee SR, Bhalla SK, Bloom J, Hayes RL, et al. Survival of patients with glioblastoma multiforme is not influenced by altered expression of p16, p53, EGFR, MDM2 or Bcl-2 genes. Brain Pathol 1998; 4: 655-67.
19. Ichimura K, Schmidt EE, Goike HM, Collins VP. Human glioblastomas with no alterations of the CDKN2A (p16INK4A, MTS1) and CDK4 genes have frequent mutations of the retinoblastoma gene. Oncogene 1996; 13: 1065-72.
20. Ichimura K, Bolin MB, Goike HM, Schmidt EE, Moshref A, Collins VP. Deregulation of the p14ARF/MDM2/p53 pathway is a prerequisite for human astrocytic gliomas with G1-S transition control gene abnormalities. Cancer Res 2000; 60: 417-24.
21. Lin H, Bondy ML, Langford LA, Hess KR, Delclos GL, Wu X, et al. Allelic deletion analyses of MMAC/PTEN and DMBT1 loci in gliomas: relationship to prognostic significance. Clin Cancer Res 1998; 4: 2447-54.
22. Von Deimling A, Bender B, Jahnke R, Waha A, Kraus J, Albrecht S, et al. Loci associated with malignant progression in astrocytomas: a candidate on chromosome 19q. Cancer Res 1994; 54: 1397-401.
23. Hoang-Xuan K, He J, Huguet S, Mokhtari K, Marie Y, Kujas M, et al. Molecular heterogeneity of oligodendrogliomas suggests alternative pathways in tumor progression. Neurology 2001; 57: 1278-81.
24. Kleihues P, Ohgaki H. Primary and secondary glioblastomas: from concept to clinical diagnosis. Neurooncol 1999; 1: 44-51.
25. Tohma Y, Gratas C, Biernat W, Peraud A, Fukuda M, Yonekawa Y, et al. PTEN (MMAC1) mutations are frequent in primary glioblastomas (de novo) but not in secondary glioblastomas. J Neuropathol Exp Neurol 1998; 57: 684-9.
26. Bietnat W, Kleihues P, Yonekawa Y, Ohgaki H. Amplification and overexpression of MDM2 in primary (de novo) glioblastomas. J Neuropathol Exp Neurol 1991; 56: 180-5.
27. Nakamura M, Yang F, Fujisawa H, Yonekawa Y, Kleihues P, Ohgaki H. Loss of heterozygosity on chromosome 19 in secondary glioblastomas. J Neuropathol Exp Neurol 2000; 59: 539-43.
28. Pollack IF, Finkelstein SD, Woods J, Burnham J, Holmes EJ, Hamilton RL, et al. Children's Cancer Group. Expression of p53 and prognosis in children with malignant gliomas. N Engl J Med 2002; 346: 420-7.
29. Van Meyel DJ, Ramsay DA, Casson AG, Keeney M, Chambers AF, Cairncross JG. p53 mutation, expression, and DNA ploidy in evolving gliomas: evidence for two pathways of progression. J Natl Cancer Inst 1994; 86: 1011-7.
30. Barker FG, Simmons ML, Chang SM, Prados MD, Larson DA, Sneed PK, et al. EGFR overexpression and radiation response in glioblastoma multiforme. Int J Radiat Oncol Biol Phys 2001; 51: 410-8.
31. Galanis E, Buckner J, Kimmel D, Jenkins R, Alderete B, O'Fallon J, et al. Gene amplification as a prognostic factor in primary and secondary high-grade malignant gliomas. Int J Oncol 1998; 13: 717-24.
32. Etienne MC, Formento JL, Lebrun-Frenay C, Gioanni J, Chatel M, Paquis P, et al. Epidermal growth factor receptor and labeling index are independent prognostic factors in glial tumor outcome. Clin Cancer Res 1998; 4: 2383-90.
33. Chakravarti A, Zhai G, Suzuki Y, Sarkesh S, Black PM, Muzikansky A, et al. The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas. J Clin Oncol 2004; 22: 1926-33.
34. Shinojima N, Tada K, Shiraishi S, Kamiryo T, Kochi M, Nakamura H, et al. Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. Cancer Res 2003; 63: 6962-70.
35. Ohgaki H, Eibl RH, Wiestler OD, Yasargil MG, Newcomb EW, Kleihues P. p53 mutations in nonastrocytic human brain tumors. Cancer Res 1991; 51: 6202-5.
36. Cairncross JG, Ueki K, Zlatescu MC, Lisle DK, Finkelstein DM, Hammond RR, et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 1998; 90: 1473-9.
37. Reifenberger J, Reifenberger G, Liu L, James CD, Wechsler W, Collins VP. Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p. Am J Pathol 1994; 145: 1175-90.
38. Kraus JA, Koopmann J, Kaskel P, Maintz D, Brandner S, Schramm J, et al. Shared allelic losses on chromosomes 1p and 19q suggest a common origin of oligodendroglioma and oligoastrocytoma. J Neuropathol Exp Neurol 1995; 54: 91-5.
39. Smith JS, Alderete B, Minn Y, Borell TJ, Perry A, Mohapatra G, et al. Localization of common deletion regions on 1p and 19q in human gliomas and their association with histological subtype. Oncogene 1999; 18: 4144-52.
40. Bigner SH, Matthews MR, Rasheed BK, Wiltshire RN, Friedman HS, Friedman AH, et al. Molecular genetic aspects of oligodendrogliomas including analysis by comparative genomic hybridization. Am J Pathol 1999; 155: 375-86.
41. Ino Y, Zlatescu MC, Sasaki H, Macdonald DR, Stemmer-Rachamimov AO, Jhung S, et al. Long survival and therapeutic responses in patients with histologically disparate high-grade gliomas demonstrating chromosome 1p loss. J Neurosurg 2000; 92: 983-90.
42. Husemann K, Wolter M, Buschges R, Bostrom J, Sabel M, Reifenbetger G. Identification of two distinct deleted regions on the short arm of chromosome 1 and rare mutation of the CDKN2C gene from 1p32 in oligodendroglial tumors. J Neuropathol Exp Neurol 1999; 58: 1041-50.
43. Iuchi T, Namba H, Iwadate Y, Shishikura T, Kageyama H, Nakamura Y, et al. Identification of the small interstitial deletion at chromosome band 1p34-p35 and its association with poor outcome in oligodendroglial tumors. Genes Chromosomes Cancer 2002; 35: 170-5.
44. Hashimoto N, Murakami M, Takahashi Y, Fujimoto M, Inazawa J, Mineura K. Correlation between genetic alteration and long-term clinical outcome of patients with oligodendroglial, tumors, with identification of a consistent region of deletion on chromosome arm 1p. Cancer 2003; 97: 2254-61.
45. Rosenberg JE, Lisle DK, Burwick JA, Ueki K, von Deimling A, Mohtenweiser HW, et al. Refined deletion mapping of the chromosome 19q glioma tumor suppressor gene to the D19S412-STD interval. Oncogene 1996; 13: 2483-5.
46. Tsujimoto T, Mochizuchi S, Iwadate Y, et al. The p73 gene is not mutated in oligodendrogliomas which frequently have a deleted region at chromosome 1p36.3. Anticancer Res 2000; 20: 2495-7.
47. He J, Hoang-Xuan K, Marie Y, Mokhtari K, Kujas M, Delattre JY, et al. P18 gene and progression of oligodendrogliomas to anaplasia. Neurology 2000; 55: 867-70.
48. Smith JS, Tachibana I, Pohl U, et al. A transcript map of the chromosome 19q-arm glioma tumor suppressor region. Genomics 2000; 64: 44-50.
49. Sato K, Schauble B, Kleihues P, Ohgaki H. Infrequent alterations of the p15, p16, CDK4 and cyclin D1 genes in non-astrocytic human brain tumors. Int J Cancer 1996; 66: 305-8.
50. Reifenberger J, Reifenberger G, Ichimura K, et al. Epidermal growth factor receptor expression in oligodendroglial tumors. Am J Pathol 1996; 149: 29-35.
51. Sasaki H, Zlatescu MC, Betensky RA, Ino Y, Cairncross JG, Louis DN. PTEN is a target of chromosome 10q loss in anaplastic oligodendrogliomas and PTEN alterations are associated with poor prognosis. Am J Pathol 2001; 159: 359-67.
52. Sanson M, Leuraud P, Marie Y, Delattre JY, Hoang-Xuan K. Preferential loss of paternal 19q, but not 1p alleles in oligodendroglial tumors. Ann Neurol 2002; 52: 105-7.
53. Hagel C, Laking G, Laas R, Scheil S, Jung R, Midle-Langosch K, et al. Demonstration of p53 protein and TP53 gene mutations in oligodendrogliomas. Eur J Cancer 1996; 32A: 2242-8.
54. Watanabe T, Yokoo H, Yokoo M, Yonekawa Y, Kleihues P, Ohgaki H. Concurrent inactivation of RB1 and TP53 pathways in anaplastic oligodendrogliomas. J Neuropathol Exp Neurol 2001; 60: 1181-9.
55. Wolter. 2001.
56. Jeuken JWM, Sprenger SHE, Wesseling P, et al. Identification of subgroups of high grade oligodendroglial tumors by comparative genomic hybridization. J Neuropathol Exp Neurol 1999; 58: 606-12.
57. Jeuken JW, Sprenger SH, Vermeer H, Kappelle AC, Boerman RH, Wesseling P. Chromosomal imbalances in primary oligodendroglial tumors and their recurrences: clues about malignant progression detected using comparative genomic hybridization. J Neurosurg 2002; 96: 559-64.
58. Sasaki H, Zlatescu MC, Betensky RA, Johnk LB, Cutone AN, Cairncross JG, et al. Histopathological-molecular genetic correlations in referral pathologist-diagnosed low-grade "oligodendroglioma". J Neuropathol Exp Neurol 2002; 61: 58-63.
59. Godfraind C, Rousseau E, Ruchoux MM, Scaravilli F, Vikkula M. Tumour necrosis and microvascular proliferation are associated with 9p deletion and CDKN2A alterations in 1p/19q-deleted oligodendrogliomas. Neuropathol Appl Neurobiol 2003; 29: 462-71.
60. Marie Y, Sanson M, Mokhtari K, Leuraud P, Kujas M, Delattre JY, et al. OLIG2 as a specific marker of oligodendroglial tumour cells. Lancet 2001; 358: 298-300.
61. Aguirre-Cruz L, Mokhtari K, Hoang-Xuan K, Marie Y, Crinière E, Taillibert S, et al. Analysis of the bHLH transcription factors Olig1 and Olig2 in brain tumors. J Neurooncol 2004; 67: 265-71.
62. Mokhtari K, Paris S, Aguirre-Cruz L, et al. Olig2 expression, GFAP, p53 and 1p loss analysis contribute to glioma subclassification. Neuropathol Appl Neurobiol 2005; 31: 62-9.
63. Zlatescu MC, TehraniYazdi A, Sasaki H, Megyesi JF, Betensky RA, Louis DN, et al. Tumor location and growth pattern correlate with genetic signature in oligodendroglial neoplasms. Cancer Res 2001; 61: 6713-5.
64. Mueller W, Harrmann C, Hoffmann A, Lanksch W, Kiwit J, Tonn J, et al. Genetic signature of oligoastrocytomas correlates with tumor location and denotes distinct molecular subsets. Am J Pathol 2002; 161: 313-9.
65. Laigle-Donadey F, Martin-Duverneuil N, Crinière E, Paris S, Marie Y, Leuraud P, et al. Correlations between molecular profile and radiological pattern in oligodendroglial tumors. Neurology 2004; 63: 2360-2.
66. Spassky N, Heydon K, Mangatal A, Jankovski A, Olivier C, Quetaud-Lesaux F, et al. Sonic hedgehog-dependent emergence of oligodendrocytes in the telencephalon: evidence for a source of oligodendrocytes in the olfactory-bulb that is independent of PDGFRalpha signaling. Development 2001; 128: 4993-5004.
67. Ino Y, Betensky RA, Zlatescu MC, Sasaki H, Macdonald DR, Stemmer-Rachamimov AO, et al. Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis. Clin Cancer Res 2001; 7: 839-45.
68. Sasaki H, Betensky RA, Cairncross JG, Louis DN. DMBT1 polymorphisms: relationship to malignant glioma tumorigenesis. Cancer Res 2002; 62: 790-6.
69. Hoang-Xuan K, Capelle L, Kujas M, Taillibert S, Duffau H, Lejeune S, et al. Temozolomide as initial treatment for adults with low grade oligodendrogliomas or oligo-astrocytomas and correlation with chromosome 1p deletions. J Clin Oncol 2004; 22: 3133-8.
70. Smith JS, Perry A, Borell TJ, Lee HK, O'Fallon J, Hosek SM, et al. Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J Clin Oncol 2000; 18: 636-45.
71. Van den Bent M, Kros JM, Heimans JJ, et al. Response rate and prognostic factors of recurrent oligodendroglioma treated with PCV chemotherapy. Neurology 1998; 51: 1140-5.
72. Fallon KB, Palmer CA, Roth KA, Nabors LB, Wang W, Carpenter M, et al. Prognostic value of 1p, 19q, 9p, 10q, and EGFR-FISH analyses in recurrent oligodendrogliomas. J Neuropathol Exp Neurol 2004; 63: 314-22.
73. Bortolotto S, Chiado-Piat L, Cavalla P, Bosone I, Chio A, Mauro A, et al. CDKN2A/p16 inactivation in the prognosis of oligodendrogliomas. Int J Cancer 2000; 88: 554-7.
74. Sanson M, Leuraud P, Aguirre-Cruz L, He J, Marie Y, Cartallat-Carel S, et al. Loss on 10q, PTEN and DMBT1 analysis in oligodendrogliomas. J Neurosurg 2002; 97: 1397-401.
75. Dong ZQ, Pang JC, Tong CY, Zhou LF, Ng HK. Clonality of oligoastrocytomas. Hum Pathol 2002; 33: 528-35.
76. Mainrz D, Fiedler K, Koopmann J, Rollbrocker B, Nechev S, Lenartz D, et al. Molecular generic evidence for subtypes of oligoastrocytomas. J Neuropathol Exp Neurol 1997; 56: 1098-104.
77. Fuller CE, Schmidt RE, Roth KA, Burger PC, Scheithauer BW, Banerjee R, et al. Clinical utility of fluorescence in situ hybridization (FISH) in morphologically ambiguous gliomas with hybrid oligodendroglial/astrocytic features. J Neuropathol Exp Neurol 2003; 62: 1118-28.
78. Jeuken JWM, Sprenger SHE, Boerman RH, Von Deimling A, Teepen HLJM, Van Overbeecke, et al. Subtyping of oligo-astrocytic tumors by comparative genomic hybridization. J Pathol 2001; 194: 81-7.
79. Daumas-Duport C, Beuvon F, Varlet P, Fallet-Bianco C. Gliomas: WHO and Sainte-Anne Hospital classifications. Ann Pathol 2000; 20: 413-28.
80. Kyritsis AP, Yung WKA, Bruner J, et al. The treatment of anaplastic oligodendrogliomas and mixed gliomas. Neurosurgery 1993; 32: 365-71.
81. Kim L, Hochberg FH, Thornton AF, Harsh 4th GR, Patel H, Finkelstein D, et al. Procarbazine, lomustine, and vincristine (PCV) chemotherapy for grade III and grade IV oligoastrocytomas. J Neurosurg 1996; 85: 602-7.
82. Cowell JK, Barnett GH, Nowak NJ. Characterization of the 1p/19q chromosomal loss in oligodendrogliomas using comparative genomic hybridization arrays (CGHa). J Neuropathol Exp Neurol 2004; 63: 151-8.
83. Godard S, Getz G, Delorenzi M, Farmer P, Kobayashi H, Desbaillets I, et al. Classification of human astrocytic gliomas on the basis of gene expression: a correlated group of genes with angiogenic activity emerges as a strong predictor of subtypes. Cancer Res 2003; 63: 6613-25.
84. Nutr CL, Mani DR, Betensky RA, Tamayo P, Cairncross JG, Ladd C, et al. Gene expression-based classification of malignant gliomas correlates better with survival than histological classification. Cancer Res 2003; 63: 1602-7.